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Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) is the most common
hereditary subcortical vascular dementia. It is caused by mutations in NOTCH3 gene, which encodes a large transmembrane
receptor Notch3. The key pathological ﬁnding is the accumulation of granular osmiophilic material (GOM), which contains
extracellular domains of Notch3, on degenerating vascular smooth muscle cells (VSMCs). GOM has been considered
speciﬁcally diagnostic for CADASIL, but the reports on the sensitivity of detecting GOM in patients’ skin biopsy have been
contradictory. To solve this contradiction, we performed a retrospective investigation of 131 Finnish, Swedish and French
CADASIL patients, who had been adequately examined for both NOTCH3 mutation and presence of GOM. The patients
were examined according to the diagnostic practice in each country. NOTCH3 mutations were assessed by restriction
enzyme analysis of speciﬁc mutations or by sequence analysis. Presence of GOM was examined by electron microscopy
(EM) in skin biopsies. Biopsies of 26 mutation-negative relatives from CADASIL families served as the controls. GOM was
detected in all 131 mutation positive patients. Altogether our patients had 34 different pathogenic mutations which included
three novel point mutations (p.Cys67Ser, p.Cys251Tyr and p.Tyr1069Cys) and a novel duplication (p.Glu434_Leu436dup).
The detection of GOM by EM in skin biopsies was a highly reliable diagnostic method: in this cohort the congruence
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exact ﬁgure for sensitivity cannot be determined, but it would require a prospective study to exclude possible selection
bias. The identiﬁcation of a pathogenic NOTCH3 mutation is an indisputable evidence for CADASIL, but demonstration of
GOM provides a cost-effective guide for estimating how far one should proceed with the extensive search for a new or
an uncommon mutations among the presently known over 170 different NOTCH3 gene defects. The diagnostic skin biopsy
should include the border zone between deep dermis and upper subcutis, where small arterial vessels of correct size are
located. Detection of GOM requires technically adequate biopsies and distinction of true GOM from fallacious deposits.
If GOM is not found in the ﬁrst vessel or biopsy, other vessels or additional biopsies should be examined.
Keywords: CADASIL; GOM; skin biopsy; NOTCH3; genetic testing
Abbreviations: CADASIL=cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy;
EGF=epidermal growth factor; EM=electron microscopy; GOM=granular osmiophilic material; VSMC=vascular smooth
muscle cells
Introduction
Cerebral autosomal dominant arteriopathy with subcortical infarcts
and leukoencephalopathy (CADASIL), the most common heredi-
tary vascular dementia, is characterized by migraineous headache
with aura, recurrent ischaemic attacks, cognitive decline and
psychiatric symptoms as the four main features. It is caused by
mutations in NOTCH3 gene encoding a transmembrane receptor
Notch3 (Joutel et al., 1996). Virtually all pathogenic mutations
lead to an odd number of cysteine residues in one of the 34
epidermal growth factor (EGF) like repeats in the extracellular
domain of Notch3 (N3ECD). The mutations result in a degenera-
tion of vascular smooth muscle cells (VSMC), in which NOTCH3 is
predominantly expressed in adult humans (Joutel et al., 2000a).
The main pathological ﬁndings are accumulation of N3ECD on
degenerating VSMCs as well as ﬁbrosis and thickening of arterial
walls, (Ruchoux et al., 1995; Miao et al., 2004). In electron
microscopy (EM), the pathognomonic feature of CADASIL is accu-
mulation of granular osmiophilic material (GOM) in indentations
of the VSMCs or in the extracellular space in close vicinity to
VSMCs (Baudrimont et al., 1993; Ruchoux et al., 1995). The
exact composition of GOM has not been elaborated, but a
recent immunogold EM study suggested N3ECD to be a com-
ponent of GOM (Ishiko et al., 2006).
CADASIL is suspected in patients with the typical clinical
features and white matter alterations in brain T2-weighted MRI
(O’Sullivan et al., 2001). The deﬁnite veriﬁcation of the diag-
nosis can be done by identifying a pathogenic mutation in the
NOTCH3 gene. In CADASIL, at least 170 different mutations in
20 different exons have been reported (Supplementary Table 1).
Comprehensive analysis of all these exons is time consuming and
costly. Thus, most diagnostic laboratories screen only the exons
that according to the previous reports harbour majority of the
mutations (Joutel et al., 1997; Escary et al., 2000; Kalimo et al.,
2002; Opherk et al., 2004; Dotti et al., 2005).
Already before the underlying gene defect was discovered,
GOM was detected by EM in skin biopsies from CADASIL
patients (Ruchoux et al., 1994). So far GOM has not been
described in any other disease entity. However, the reports
on the sensitivity of detecting GOM in skin biopsy of patients
with genetically veriﬁed CADASIL have been contradictory.
Two earlier studies on a smaller number of patients (Ebke et al.,
1997; one family with eight patients, mutation not speciﬁed;
Mayer et al., 1999; three families, 14 patients, mutations not
speciﬁed) suggested 100% sensitivity and speciﬁcity, whereas
two more recent papers have reported a low sensitivity: Markus
et al. (2002) reported a sensitivity of only 44.4% (eight out of 18),
while Razvi et al. (2003) suspected that the sensitivity might be
even lower, although they did not give an exact number. To solve
this contradiction, we performed a retrospective investigation of
a combined patient material from Finland, Sweden and France
comprising 131 patients, from whom both the genetic analysis
and EM examination of skin biopsy were available. Skin biopsies
from 26 mutation negative members of genetically proven
CADASIL families served as control. We showed that electron
microscopic demonstration of GOM in skin biopsy is a highly
reliable and practical method to screen for or even speciﬁcally
diagnose CADASIL. Furthermore, the intensive search for muta-
tions based on conﬁdence in the diagnostic speciﬁcity of GOM
resulted in discovery of four novel, previously unreported muta-
tions, among them the ﬁrst duplication of three codons.
Materials and Methods
Subjects
The subjects comprise of 131 patients in whom both the analysis of
NOTCH3 gene and EM examination of skin biopsy had been ade-
quately performed (38 from Finland, 13 from Sweden and 80 from
France) as well as 26 control subjects (mutation negative members
of the patients’ families: four from Finland, two from Sweden and
20 from France). Genetic analyses and biopsy examinations were, in
general, performed without knowledge of the other test result.
However, these analyses were part of the true clinical practice with
the aim to establish the patient’s diagnosis with all possible diagnostic
methods, thus in several cases the detection of GOM in skin biopsy
led to extended genetic analyses. Only a single subject, in whose
biopsy no representative vessels of correct size were identiﬁed, was
excluded from the study. Subjects have been clinically examined at
different hospitals in Finland, Sweden or France as well as in different
international hospitals from which blood and biopsy samples have
been sent to France for diagnostic CADASIL analyses.
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In Finland and Sweden, the diagnostic genetic analyses were originally
limited to restriction enzyme analysis of two previously found muta-
tions in Finland (p.Arg133Cys and p.Arg182Cys) and in negative
cases complemented by sequence analysis of exons 3 and 4. Because
the skin biopsy had shown presence of GOM in nine Finnish
and Swedish suspected CADASIL patients without mutation being
detected, an extended genetic analysis for NOTCH3 was established.
For the detection of CADASIL type NOTCH3, mutation exons 2–24
of gene were ampliﬁed with speciﬁc primers and subsequently
amplicons were sequenced using an automated sequencing system
(Applied Biosystems, Foster City, CA, USA).
Blood samples from hospitals in France and other countries were
sent to Laboratoire de Cytoge ´ne ´tique, Ho ˆpital Lariboisie `re, Paris,
France and analysed as a commercial diagnostic service.
Electron microscopy
In Finland and Sweden, skin biopsies were requested from as many
CADASIL suspected patients as possible, especially from those with a
strong suspicion of CADASIL and negative result in limited genetic
tests mentioned above. The skin biopsies were taken at the hospitals,
where the CADASIL patients or their relatives were examined. Either
full thickness punch biopsies or small incision biopsies were taken
(usually from the upper arm) and ﬁxed in phosphate buffered 3–4%
glutaraldehyde, in which solution the biopsies were sent in Finland to
the Laboratory of Electron Microscopy of the University of Turku or
Helsinki, in Sweden to the Laboratory of Electron Microscopy at
the Department of Pathology, University of Uppsala. In France the
biopsies ﬁxed in either Carson or Trump liquids or as above were
sent to the Laboratories of Electron Microscopy at Ho ˆpital Roger
Salengro, University of Lille or Ho ˆpital Bretonneau, University of
Tours, France. The samples were postﬁxed in buffered osmium
tetroxide, dehydrated in ascending grades of ethanol and embedded
in Epon. Semithin sections were cut and stained with toluidine blue
for selecting arteries of appropriate size (usually in the borderzone
between dermis and subcutis) for thin sectioning. Thin sections were
double stained with uranyl acetate and lead citrate and then exam-
ined in transmission electron microscopes at the EM laboratories
mentioned above. The Finnish and Swedish skin biopsies were
analysed by two Finnish (S.T. and H.K.) electron microscopists and
in France by a French (MMR) electron microscopist.
Results
Altogether, GOM was detected in skin biopsies from all 131
patients, who in the genetic analyses were determined to carry
a pathogenic NOTCH3 mutation for CADASIL (Table 1). GOM
was present above all in arterial vessels, whereas the veins and
capillaries were either GOM negative or seldom GOM positive
(Figs 1 and 2). In most GOM positive cases, GOM was detected
in the ﬁrst biopsy but in a few cases a repeated biopsy was
needed. During the diagnostic activity, we examined many
suspected cases in whose biopsies we detected, instead of
GOM, cellular debris between the VSMCs with structure
that might lead unfamiliar electron microscopists astray. These
cases were also negative in genetic tests (limited to the
common mutations). Some common deposits of fallacious appear-
ance are shown in Fig. 3.
Representative skin biopsies were negative for GOM in the
26 subjects, who were also negative for the NOTCH3 mutation
that was detected in their relatives. Therefore, these subjects were
identiﬁed as deﬁnite negative cases for CADASIL.
In Finland and Sweden, GOM was detected in 51 patients, from
28 families with veriﬁed NOTCH3 mutations. In these families 12
different NOTCH3 mutations were identiﬁed, among these three
point mutations (p.Cys67Ser, p.Cys251Tyr and p.Tyr1069Cys) and
one duplication (p.Glu434_Leu436dup, producing an unpaired
cysteine in the affected EGF repeat) were novel, previously unpub-
lished (Table 1). In one Finnish patient, repeated skin biopsies
were positive for GOM, although no mutation was found in
screening of the NOTCH3 exons 2–24. Repeated genetic analysis
with another set of primers revealed a heterozygous c.1582GT
(p.Gly528Cys) mutation.
Table 1 The spectrum of NOTCH3 mutations in combined
CADASIL patient cohort from Finland, Sweden and France
Amino acid change Nucleotide change
in coding sequence
Exon Finnish (F)
French (Fr)
Swedish (S)
1 p.Cys49Tyr c.146G4A2 F r
2 p.Cys67Ser
a c.199T4A3 S
3 p.Thr71Cys c.213G4T3 F r
4 p.Arg90Cys c.268C4T 3 Fr/S
5 p.Arg110Cys c.328C4T3 F r
6 p.Arg133Cys c.397C4T 4 F/Fr/S
7 p.Cys134Trp c.402C4G4 F r
8 p.Arg141Cys c.421C4T4 F r
9 p.Arg169Cys c.505C4T4 F r
10 p.Gly171Cys c.511G4T4 F r
11 p.Cys174Arg c.520T4C4 S
12 p.Arg182Cys c.544C4T 4 Fr/S
13 p.Cys185Arg c.553T4C4 F r
14 p.Cys185Gly c.553T4G4 F r
15 p.Cys206Tyr c.617G4A4 S
16 p.Cys212Ser c.634T4A4 F r
17 p.Cys222Gly c.664T4G4 F r
18 p.Cys224Tyr c.671G4A4 F r
19 p.Cys251Tyr
a c.752G4A5 S
20 p.Tyr258Cys c.773A4G5 F r
21 p.Arg332Cys c.994C4T6 S
22 p.Cys428Ser c.1283G4C8 F r
23 p.Glu434_Leu436dup
a c.1300_1308dup 8 F
24 p.Gly528Cys c.1660G4T1 0 F
25 p.Cys542Tyr c.1625G4A1 1 F r
26 p.Arg558Cys c.1672C4T 11 Fr/S
27 p.Arg578Cys c.1732C4T1 1 F r
28 p.Arg728Cys c.2182C4T1 4 F r
29 p.Arg985Cys c.2953C4T1 8 F r
30 p.Arg1006Cys c.3016C4T1 9 F r
31 p.Arg1031Cys c.3091C4T1 9 F r
32 p.Tyr1069Cys
a c.3206A4G2 0 F
33 p.Arg1231Cys c.3691C4T2 2 F r
34 p.Cys1261Arg c.3782T4C2 3 F r
a Mutation previously unpublished.
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mutation positive patients—not only from France but also from
different parts of the world. Among the patients whose DNA
samples were analysed in France 26 different NOTCH3 mutations
were identiﬁed (Table 1).
Discussion
In our patients’ detection of GOM from skin biopsy was a highly
reliable method for the diagnostic workup of suspected CADASIL
patients. GOM was detected in the skin biopsy of all 131 patients,
in whom the NOTCH3 mutation had been identiﬁed and a repre-
sentative skin biopsy was available. Thus the congruence was
100%. This study was performed retrospectively and therefore
to exclude possible selection bias a prospective study would be
required to get an exact ﬁgure for sensitivity, which we estimate
to be well over 90%. The genetic analysis and EM detection of
GOM were primarily made simultaneously and blinded to each
other. Since the analysis has been made as a part of the diag-
nostic work, the EM analysis has been used to support the
restricted genetic testing. In some cases, the GOM positive EM
analysis prompted us to screen the NOTCH3 exons 2–24. During
the examinations of suspected patients in some cases, no rep-
resentative vessels were detected. A repeated biopsy was
requested and if the biopsy was still non-representative the case
was excluded from this study. Most often the parallel genetic
analysis (limited as mentioned above) of these patients proved
negative. Since our resources did not allow full sequencing of
exons 2–24 in all suspected patients, CADASIL diagnosis could
not be excluded in these patients with absolute certainty. In
only one NOTCH3 mutation positive patient, we did not ﬁnd
representative vessels in the only available biopsy, and thus, the
presence of GOM could not be determined. Based on the inclu-
sion criteria this patient had to be excluded from this cohort.
When using EM analysis of skin biopsy as a diagnostic method
in suspected CADASIL cases, special attention should be paid to
the quality and analysis of the skin biopsy. The vessels in which
the GOM is best detectable are generally medium sized or small
arterioles (usually outer diameter 20–40mm) in deep dermis or
upper subcutis, but in a few cases GOM has been detected also
in veins. In toluidine blue semi-thin sections the detection of
lamina elastica interna as dark blue dots (Fig. 1) is a good
marker of representative arterioles. Technical factors in the pro-
cessing of the samples may also inﬂuence the result. Since GOM
is osmiophilic, each laboratory should adjust the osmium tetroxide
treatment such that GOM becomes sufﬁciently well contrasted.
Furthermore, if GOM is not found in the ﬁrst vessel investigated,
other vessels or even repeat biopsies should be examined. Just like
in any laboratory work, ﬁrst negative result might be due to an
unrepresentative sample or improper sample handling. Besides,
one should examine rather an artery (with multiple layers of
VSMCs and inner elastic lamina) than a vein or a capillary, since
according to our experience veins and capillaries are not always
GOM positive (Fig. 2). Of course, a prerequisite is that one
recognizes GOM correctly and distinguishes it from fallacious
deposits (Fig. 3).
Figure 1 A small arteriole (left) and venule (right) in the
lower dermis of the skin biopsy from a Finnish CADASIL
patient with p.Arg133Cys mutation. Note the somewhat
thicker wall and lamina elastica interna (dark blue spots
beneath the endothelium) in the arteriole. Toluidine
blue-stained semithin epon section.
Figure 2 (A) The same vein as in Fig. 1 with no GOM.
(B) A vein from deep dermis with one deﬁnite GOM deposit
(arrow) shown at a higher magniﬁcation in the inset.
(C) The arteriole in Fig. 1 with several GOM deposits
(ﬁve shown with arrows), one marked with asterisk is shown
at a higher magniﬁcation in the inset. Note the characteristic
pinocytotic vesicles at the VSMC plasma membrane beneath
the GOM. L=lumen, E=endothelium, M=vascular smooth
muscle cell.
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search for mutations to sequencing the exons 2–24 in the nine
patients in whom the limited mutation analyses had been nega-
tive. The detection of four novel mutations demonstrated that
even though over 170 different NOTCH3 mutations are known,
the presence of six cysteines in each of the translated 34 EGF
repeats which may be replaced by another amino acid in addi-
tion to the replacement of other amino acids by cysteine,
A B
C D
E F
Figure 3 Fallacious deposits which may lead the electron microscopist astray. (A) True GOM with a somewhat exceptional mushroom-
like form (arrows). Note the characteristic ﬁnely granular structure of GOM. (B) Fragments of elastica interna (ELA) and granular ﬁbrillin
network (F) in the widened subendothelial space. (C) Granular debris of unknown origin (asterisk). (D) Similar granular material as in
C (arrow) with a misleading localization in a cove of VSMCs. (E and F) Small clumps of cell debris of different composition (arrows),
possibly from degenerated cells. L=lumen, E=endothelium, M=vascular smooth muscle cell.
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This multitude is further widened by possibility of deletions
(Dichgans et al., 2000, 2002; Opherk et al., 2004) and splice
site mutations (Joutel et al., 2000b).
In one Finnish patient with GOM positive skin biopsy the
NOTCH3 mutation was not detected until the analysis was
performed with another set of primers (at Ho ˆpital Lariboisie `re,
the most experienced diagnostic CADASIL laboratory). This
experience further emphasizes the value of skin biopsy exam-
ination as a guide for more comprehensive genetic analyses.
What would be the most efﬁcient strategy to conﬁrm the clin-
ical suspicion of CADASIL? This strongly depends on the patient’s
family history and the mutational background in the population
to which the suspected patient belongs. In families with a known
mutation, the method of choice is, of course, to test directly for
that mutation. If there are known founder or major mutations in
the population, the diagnostic workup is best to begin by ﬁrst
searching for those mutations. In populations with no known
founder or other determined mutations, screening of mutational
hot spot region of the NOTCH3 gene should be the ﬁrst genetic
method to search for CADASIL. Of the all reported pathogenic
NOTCH3 mutations 62% locate in exons 3, 4, 5 and 8. Further-
more, to obtain 80% coverage, additional investigation of exons
2, 6, 11 and 18 is required (Supplementary Table 1). At the latest
after these analyses electron microscopy for GOM is highly
recommended. Similar approach has been suggested by Peters
et al. (2005). Mutation screening covering the whole region
coding for EGF repeats (exons 2–24) is not realistic for all patients
and for most laboratories.
In cases with at least a fair amount of accumulated N3ECD
the immunostaining has been found reliable (Joutel et al., 2001).
However, if only a small amount of the N3ECD has accumulated,
e.g. at the early stage of the disease, ultrastructural resolution
and characteristic appearance of GOM most likely make the EM
analysis more reliable: we have detected GOM even in patients
below the age of 20 years (Fig. 4). Besides, non-speciﬁc staining
is an inherent caveat of immunohistochemistry (Lesnik Oberstein
et al., 2003), which may be problematic just in cases with small
amounts of N3ECD. Moreover, EM examination provides also
information about other pathological changes in the arterial wall,
such as those due to hypertension, ageing and possibly even
other hereditary arteriopathies (Ruchoux et al., 2000, 2002;
Brulin et al., 2002). The absence of GOM in members of the
Swedish family with multi-infarct dementia, previously thought
to be the ﬁrst published pedigree with CADASIL (Sourander and
Walinder, 1977) was an important piece of evidence in addition
to the negative genetic analyses in the demonstration that the
family suffers from another hereditary vascular dementia (Low
et al., 2007). On the other hand, the team of one of the
authors (A.J.) has just identiﬁed another cerebral small vessels
disease caused by a novel type of pathogenic mutation in the
exon 25 of NOTCH3 outside the domain with EGF like repeats
(Fouillade et al., 2008). This mutation, p.Leu1515Pro, causes
increased canonical NOTCH3 signaling in a ligand-independent
fashion, possibly due to destabilization of the Notch3 heterodimer.
Remarkably, in this single patient reported there is no deposition
of N3ECD and GOM on VSMCs.
In conclusion, the strategy of the CADASIL workup should be
based on logical evaluation of clinical ﬁndings, family history as
well as on both genetic and morphological methods available.
Demonstration of a known pathogenic mutation provides indis-
putable evidence for the disease and gives a practical tool to
clarify genetic counselling in the family. In those cases, in which
the mutation is not easy to identify or genetic analysis is not
available, skin biopsy is easy to perform and in experienced
hands EM is a highly reliable method. Neither is it time con-
suming nor excessively expensive. Importantly, it is invaluable in
guiding, how far one should proceed with the genetic analyses.
Supplementary material
Supplementary material is available at Brain online.
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